Breaking News

Ozurdex approved in EU for treatment of DME

The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press release.

Under the marketing authorization extension, the dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) is indicated for adult patients with visual impairment due to diabetic macular edema who are pseudophakic, or who were unable to undergo noncorticosteroid therapy, according to the press release.

The implant is already indicated for the treatment of macular edema following branch retinal vein occlusion and central retinal vein occlusion, as well as for the treatment of noninfectious uveitis, according to the press release. It was approved by the U.S. Food and Drug Administration on June 30.

The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press release.

Under the marketing authorization extension, the dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) is indicated for adult patients with visual impairment due to diabetic macular edema who are pseudophakic, or who were unable to undergo noncorticosteroid therapy, according to the press release.

The implant is already indicated for the treatment of macular edema following branch retinal vein occlusion and central retinal vein occlusion, as well as for the treatment of noninfectious uveitis, according to the press release. It was approved by the U.S. Food and Drug Administration on June 30.